Product Images Rizatriptan Benzoate

This is a description of a medication called Rizatriptan Benzoate ODT. It is packaged and distributed by a company called W in Holland, OH. The medication comes in a box of 18 orally disintegrating tablets, each containing 10 mg of Rizatriptan Benzoate. The medication should be kept out of children's reach and a physician should be consulted before use. The lot number of the medication is provided. The medication is distributed by Rising Health, LLC in Saddle Brook, NJ.*

The Figure 1 represents the probability of obtaining relief from headache by using rizatriptan benzoate or placebo. The plot is based on data pooled from four outpatient trials (Studies 1, 2, 3, and 4) that proved the efficacy of the medication. The plot shows the estimated probability of response over time, with patients who either took additional treatment or did not report any relief within 2 hours were censored.*

This is a Kaplan-Meier plot showing the estimated probability of patients taking a second dose of Rizatriptan Benzoate tablets or other medication for migraines over the 24 hours following the initial dose of study treatment in Pooled Studies 1,2,3, and 4. The plot includes patients who had headache response at 2 hours and those who had no response to the initial dose. Remedication was not allowed within 2 hours post-dose. The data is based on 4 placebo-controlled outpatient clinical trials.*

The given text is describing Figure 3, which shows the estimated probability of achieving a headache response with Rizatriptan Benzoate orally disintegrating tablets in two studies (5 and 6). The graph displays the Kaplan-Meier plot over time of the probability of obtaining relief from headaches following treatment with the tablets or a placebo. The data used to generate the graph is based on two outpatient trials (Studies 5 and 6) that provide evidence of efficacy. The text also mentions that patients who did not achieve headache relief within 2 hours of treatment were given additional treatment.*

The given text describes a figure labeled "Figure4" that shows the estimated probability of patients taking a second dose of Rizatriptan Benzoate Orally Disintegrating Tablets or other medication for migraines over the 24 hours following the initial dose of study treatment in pooled studies 5 and 6. The plot is a Kaplan-Mier plot based on data gained in 2 placebo-controlled outpatient clinical trials (Studies 3 and 6). The plot includes both patients who had a headache response at 2 hours and those who had no response to the initial dose. However, the output is not entirely readable due to mixed characters and gibberish, making it difficult to understand the details of the study.*